MED12 alterations in both human benign and malignant uterine soft tissue tumors

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Pérot, Gaëlle ^a   Croce, Sabrina ^a   Ribeiro, Agnès ^a   Lagarde, Pauline ^a   Velasco, Valérie ^a   Neuville, Agnès ^a   Coindre, Jean Michel ^a,b   Stoeckle, Eberhard ^a   Floquet, Anne ^a   MacGrogan, Gaëtan ^a   Chibon, Frédéric ^a  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MED12 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ALLELE; ARTICLE; CYTOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MED12 GENE; PROTEIN EXPRESSION; SOFT TISSUE TUMOR; UTERUS TUMOR;

ALLELES; BASE SEQUENCE; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; LEIOMYOMA; MEDIATOR COMPLEX; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN TRANSPORT; SMOOTH MUSCLE TUMOR; SOFT TISSUE NEOPLASMS; UTERINE NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84863096005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040015     Document Type: Article

References (48)

1. Robboy SJ, Bentley RC, Butnor K, Anderson MC, (2000) Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 108: 779-784.
2. Okolo S, (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22: 571-588.
3. Tavassoli F, Devilee P, eds. (2003) Patholology and genetics of tumours of the breast and female genital organs. In: Kleihues P, Sobin LH (eds). World Health organization classification of tumours 5, 223-249. (eds) (.
4. Bell SW, Kempson RL, Hendrickson MR, (1994) Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18: 535-558.
5. Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, et al. (2009) Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer 19: 385-390.
6. D'Angelo E, Espinosa I, Ali R, Gilks CB, Rijn M, et al. (2011) Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 121: 328-333.
7. Kir G, Eren S, Akoz I, Kir M, (2003) Leiomyosarcoma of the broad ligament arising in a pre-existing pure neurilemmoma-like leiomyoma. Eur J Gynaecol Oncol 24: 505-506.
8. Scurry J, Hack M, (1990) Leiomyosarcoma arising in a lipoleiomyoma. Gynecol Oncol 39: 381-383.
9. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB, (1990) Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 62: 968-974.
10. Lowell DM, Karsh J, (1968) Leiomyosarcoma of the broad ligament. A case report. Obstet Gynecol 32: 107-110.
11. Hart WR, Billman JK Jr, (1978) A reassessment of uterine neoplasms originally diagnosed as leiomyosarcomas. Cancer 41: 1902-1910.
12. Herbold DR, Fu YS, Silbert SW, (1983) Leiomyosarcoma of the broad ligament. A case report and literature review with follow-up. Am J Surg Pathol 7: 285-292.
13. Mittal K, Popiolek D, Demopoulos RI, (2000) Uterine myxoid leiomyosarcoma within a leiomyoma. Hum Pathol 31: 398-400.
14. Mittal K, Joutovsky A, (2007) Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol 104: 362-365.
15. Yanai H, Wani Y, Notohara K, Takada S, Yoshino T, (2010) Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review. Pathol Int 60: 506-509.
16. Hodge JC, Morton CC, (2007) Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet Spec No 1: R7-13.
17. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252-255.
18. Taatjes DJ, (2010) The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 35: 315-322.
19. Conaway RC, Conaway JW, (2011) Function and regulation of the Mediator complex. Curr Opin Genet Dev 21: 225-230.
20. Morey C, Avner P, (2011) The demoiselle of X-inactivation: 50 years old and as trendy and mesmerising as ever. PLoS Genet 7: e1002212.
21. Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, et al. (2012) MED12 mutations in uterine fibroids - their relationship to cytogenetic subgroups. Int J Cancer doi:10.1002/ijc.27424.
22. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, et al. (2012) Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas. PLoS One. 7: e33251.
23. Cho YL, Bae S, Koo MS, Kim KM, Chun HJ, et al. (2005) Array comparative genomic hybridization analysis of uterine leiomyosarcoma. Gynecol Oncol 99: 545-551.
24. Mittal KR, Chen F, Wei JJ, Rijhvani K, Kurvathi R, et al. (2009) Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol 22: 1303-1311.
25. Kim S, Xu X, Hecht A, Boyer TG, (2006) Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 281: 14066-14075.
26. Rocha PP, Scholze M, Bleiss W, Schrewe H, (2010) Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137: 2723-2731.
27. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH, (2012) Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer doi:10.1002/ijc.27610.
28. Zhang P, Zhang C, Hao J, Sung CJ, Quddus MR, et al. (2006) Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. Hum Pathol 37: 1350-1356.
29. Canevari RA, Pontes A, Rosa FE, Rainho CA, Rogatto SR, (2005) Independent clonal origin of multiple uterine leiomyomas that was determined by X chromosome inactivation and microsatellite analysis. Am J Obstet Gynecol 193: 1395-1403.
30. Mashal RD, Fejzo ML, Friedman AJ, Mitchner N, Nowak RA, et al. (1994) Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondly nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 11: 1-6.
31. Hashimoto K, Azuma C, Kamiura S, Kimura T, Nobunaga T, et al. (1995) Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 40: 204-208.
32. Han K, Lee W, Harris CP, Simsiman RC, Lee K, et al. (1994) Comparison of chromosome aberrations in leiomyoma and leiomyosarcoma using FISH on archival tissues. Cancer Genet Cytogenet 74: 19-24.
33. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
34. Szymanska J, Virolainen M, Tarkkanen M, Wiklund T, Asko-Seljavaara S, et al. (1997) Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study. Cancer Genet Cytogenet 99: 14-18.
35. Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, et al. (2010) Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 49: 560-568.
36. Uchida M, Tsukamoto Y, Uchida T, Ishikawa Y, Nagai T, et al. (2010) Genomic profiling of gastric carcinoma in situ and adenomas by array-based comparative genomic hybridization. J Pathol 221: 96-105.
37. Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, et al. (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16: 781-787.
38. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, et al. (2011) Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 18: 826-38.
39. Zavadil J, Ye H, Liu Z, Wu J, Lee P, et al. (2010) Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One 5: e12362.
40. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97: 4262-4266.
41. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, et al. (2001) Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 95: 194-197.
42. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, et al. (2005) Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18: 68-74.
43. Jung CK, Jung JH, Lee A, Lee YS, Choi YJ, et al. (2008) Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod Pathol 21: 756-763.
44. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE, (2009) Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur J Cancer 45: 2412-2417.
45. Döring B, Shynlova O, Tsui P, Eckardt D, Janssen-Bienhold, et al, (2006) Ablation of connexin43 in uterine smooth muscle cells of the mouse causes delayed parturition. J Cell Sci 119: 1715-1722.
46. E Oliva, M Nucci, (2009) Gynecologic Pathology. Goldblum eds, 289 p.
47. Fletcher CDM, Unni KK, Mertens F, (2002) World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press.
48. Hostetter G, Kim SY, Savage S, Gooden GC, Barrett M, et al. (2010) Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res 38: e9.